Aegle Therapeutics is developing a novel technology platform using extracellular vesicles isolated from mesenchymal stem cells to deliver therapeutically significant RNA, proteins and immunomodulatory agents to diseased and damaged cells in the body.

Aegle’s “cell-free” therapy is produced by a proprietary isolation technology that safely isolates clinical grade extracellular vesicles from MSCs. Our first target indication is a rare, monogenetic, pediatric disease called dystrophic epidermolysis bullosa.